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Abstract
Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors 
to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neo-
adjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or 
placebo in women with stage II/III, human epidermal growth factor receptor 2 (HER2)–negative 
breast cancer, in which we also examined whether change in maximum standardized uptake values 
corrected for lean body mass (SULmax) on 18F-FDG PET predicted pathologic complete response 
(pCR) in breast and axillary lymph nodes.
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Methods—Participants were randomly assigned to 12 wk of preoperative carboplatin (area under 
the curve of 2, weekly) and nab-paclitaxel (100 mg/m2 weekly) with vorinostat (400 mg orally 
daily, days 1–3 of every 7-d period) or placebo. All patients underwent 18F-FDG PET and 
research biopsy at baseline and on cycle 1 day 15. The primary endpoint was the pCR rate. 
Secondary objectives included correlation of change in tumor SULmax on 18F-FDG PET by cycle 
1 day 15 with pCR and correlation of baseline and change in Ki-67 with pCR.
Results—In an intent-to-treat analysis (n = 62), overall pCR was 27.4% (vorinostat, 25.8%; 
placebo, 29.0%). In a pooled analysis (n = 59), we observed a significant difference in median 
change in SULmax 15 d after initiating preoperative therapy between those achieving pCR versus 
not (percentage reduction, 63.0% vs. 32.9%; P = 0.003). Patients with 50% or greater reduction in 
SULmax were more likely to achieve pCR, which remained statistically significant in 
multivariable analysis including estrogen receptor status (odds ratio, 5.1; 95% confidence interval, 
1.3–22.7; P = 0.023). Differences in baseline and change in Ki-67 were not significantly different 
between those achieving pCR versus not.
Conclusion—Preoperative CP with vorinostat or placebo is associated with similar pCR rates. 
Early change in SULmax on 18F-FDG PET 15 d after the initiation of preoperative therapy has 
potential in predicting pCR in patients with HER2-negative breast cancer. Future studies will 
further test 18F-FDG PET as a potential treatment-selection biomarker.
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Chemotherapy is currently the only standard neoadjuvant treatment for women with triple-
negative (estrogen receptor [ER]–negative, progesterone receptor [PR]–negative, human 
epidermal growth factor receptor 2 [HER2]–negative) breast cancer and is also administered 
to women with the luminal B subtype before endocrine therapy. Many women experience 
recurrence and death despite this approach, emphasizing the need for new therapeutic 
strategies. Preclinical research supports the investigation of epigenetic modifiers such as the 
histone deacetylase inhibitor vorinostat for the treatment of breast cancer. In ER-positive 
and ER-negative breast cancer cell lines, vorinostat reduces proliferation, induces cell cycle 
arrest and modulates gene expression (1), and enhances the cytotoxicity of chemotherapy in 
in vitro models (2). Phase I investigation of the combination of vorinostat with carboplatin 
and paclitaxel was well tolerated and yielded a recommended phase II dose (3).
Prognostic and treatment-selection biomarkers for breast cancer patients, that could be 
determined at baseline or after a short duration of therapy, are also needed. Preoperative 
systemic therapy (PST) is an attractive model for the assessment of novel therapeutic agents 
and surrogate biomarkers of response (4). Pathologic complete response (pCR) after PST is 
an accepted primary endpoint in clinical trials, predicting improved disease-free and overall 
survival (5–7). Several biomarkers have been proposed that may predict pCR, including 
early changes in 18F-FDG uptake on PET (8); however, prospective studies establishing 
standardized methods and defining optimal cut points are needed to determine the clinical 
utility of this tool.
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We hypothesized that the addition of vorinostat would improve the pCR rate observed with 
PST alone in women with stage II–III, grade 2–3, HER2-negative breast cancer. We also 
hypothesized that changes by cycle 1 day 15 (C1D15) of therapy in tumor standardized 
uptake values corrected for lean body mass (SULmax) on 18F-FDG PET, and the 
proliferation index Ki-67, would predict pCR. To test these hypotheses we performed a 
double-blind, randomized, placebo-controlled multicenter phase II study of 12 wk of 
preoperative carboplatin and nanoparticle albumin-bound (nab) paclitaxel (CP) with 




Women 18 y or older, with histologically proven infiltrating carcinoma of the breast, were 
eligible if they presented with operable, clinical stage T1c, N1–3 or T2–4 lesions, any N, 
and M0. Tumors must have been HER2-negative and grade 2 or 3, with any ER or PR 
status. Eastern Cooperative Oncology Group performance status 0–1 and adequate organ 
function were required. Exclusion criteria were outlined in the clinical protocol. Women 
signed an informed consent form approved by the Institutional Review Boards of 
participating institutions.
Study Design
Before initiating the multicenter, double-blind, randomized phase II portion of the study, we 
conducted a nonrandomized, single-site open-label safety run-in phase. Participants received 
12 wk of preoperative carboplatin (area under the curve of 2, weekly) and nab-paclitaxel 
(100 mg/m2 weekly) with vorinostat (400 mg orally daily, days 1–3 of every 7-d period). 
Statistical considerations were included in the research protocol.
Participants in the phase II portion of the study were randomly assigned 1:1 to receive CP 
with vorinostat or placebo using permuted block randomization, stratified by hormone 
receptor status (ER and PR < 1% vs. ER or PR ≥ 1%). Common Terminology Criteria for 
Adverse Events, version 3.0, was used to grade toxicity. Additional nonstudy chemotherapy 
(adriamycin and cyclophosphamide [AC], per guidelines) was allowed per treating physician 
discretion before definitive surgery, for patients with incomplete response or disease 
progression on study treatment. Tumor biopsy and blood sample were requested before 
nonstudy chemotherapy.
Prophylactic growth factor support and dose modifications for toxicity were suggested in the 
research protocol. Axillary evaluation before initiating study therapy and final surgery type 
were per treating surgeon discretion. Administration of postoperative radiation and systemic 
therapies were also per discretion of the treating team, with guidelines in the research 
protocol.
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Participants underwent 18F-FDG PET/CT from midskull to midfemur level before tumor 
biopsy, as previously described, at baseline and C1D15 (9). Each site was asked to acquire 
and reconstruct a specific phantom study for central site review. That phantom was reviewed 
for a variety of quantitative features (e.g., uniformity and maximum and mean standardized 
uptake values [SUVs]) before the site was qualified for participation in the trial. Each site 
also submitted a whole-body 18F-FDG PET clinical study example for review by a physicist 
at the central site before site’s acceptance into the study. A uniform imaging protocol was 
provided to all users, which included dosing (8.14 MBq [0.22 mCi]/kg ± 20%), uptake (60 ± 
10 min), and plasma glucose recording. Imaging was not performed if plasma glucose was 
greater than 200 mg/dL. The protocol was based on our own clinicians’ 18F-FDG PET/CT 
protocol with components drawn from published protocols as well as institutional 
experience (10).
Regions of interest were captured over the entire volume of disease tissue and primary 
tumor. SULmax was collected because it is more consistent in absolute value than SUV 
from patient to patient in normal tissues, being less weight-dependent (11). Imaging and 
quantitation were centrally reviewed.
Immunohistochemistry
A study-specific core biopsy was obtained at baseline, C1D15, before nonstudy preoperative 
chemotherapy if given, and at the time of definitive surgery. Tumor biopsy at baseline and 
C1D15 was performed preferably about 4 h after vorinostat dose and before carboplatin and 
nab-paclitaxel dose. Slides were stained for Ki-67 and ER using commercially available 
monoclonal antibodies (Ki-67 [Immunotech], ER [Leicabiosystems], clone 6f11) in a CLIA 
(Clinical Laboratory Improvement Amendment)-certified laboratory and centrally quantified 
by the study pathologist.
Statistical Considerations
The primary endpoint was pCR, defined as no viable invasive cancer in the breast and axilla. 
All other cases were defined as non-pCR. The pCR rate was determined in each arm 
separately by performing an intent-to-treat (ITT) analysis of all randomized patients. 
Patients with unknown pCR status were considered pathologic nonresponders. The 
computation of associated 90% confidence intervals did not account for the sequential 
design.
The study included a concurrent randomized control arm of CP plus placebo for the primary 
endpoint. The design required 31 women per arm to detect a 25% pCR rate from null 
response rate of 10% using a Simon 2-stage design with 80% power and 10% type I error 
rate. There was no intention to formally compare the two arms. A single interim analysis for 
futility was performed once 16 patients underwent surgery in each arm by the study 
statistician and an investigator independent of the study conduct, both masked to treatment. 
A preplanned masked interim analysis for toxicity was conducted in the first 24 patients.
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Key secondary objectives were to correlate change in tumor SULmax on 18F-FDG PET by 
C1D15 with pCR and to correlate baseline and change in Ki-67 with pCR. Percentage 
reduction in SULmax treated as a continuous variable was compared between responders 
and non-responders using the nonparametric Wilcoxon rank sum test and the Fisher exact 
test when dichotomized at a predefined threshold (≥50% reduction). A receiver-operating-
characteristic curve analysis was performed to explore the best cutoff of SULmax reduction 
and its predictive accuracy for pCR. The association of baseline and change in SULmax or 
Ki-67 with pCR was evaluated using logistic regression models, with adjustment for 
hormone receptor status in multivariable analysis. Additional unplanned post hoc analyses, 
performed for both primary and secondary objectives, considered patients who received 
additional therapies before surgery as pathologic nonresponders.
Safety analysis included patients who received at least 1 dose of any study drug. All 
quantitative parameters were expressed as mean ± SD or median and range. All statistical 
tests were 2-sided and considered statistically significant at a P value of less than 0.05. The 
analyses were performed using SAS (version 9.2; SAS Institute) and R software packages 
(version 2.15.2). The research protocol and article were written by the authors and reviewed 
by the pharmaceutical funders, who had no access to the study database and were not 
involved in study analysis or interpretation of results.
RESULTS
Safety Run-in
Six patients were enrolled in the safety run-in phase. The combination was well tolerated, 
with predominantly grade 1 and 2 adverse events. The recommended phase II dose for CP 
was as described in the “Study Design” section, in combination with 400 mg of vorinostat or 
placebo.
Phase II
Patient Characteristics—From October 2009 to November 2011, 62 women enrolled in 
the study, with patient characteristics well balanced across treatment groups (Table 1). Of 
the 62 randomized, 61 completed study drugs and 60 completed primary surgery. Two 
patients with unknown pCR status were regarded as pathologic nonresponders on an ITT 
basis. Eighteen of 60 women (6 vorinostat arm, 12 placebo arm) also received preoperative 
nonstudy chemotherapy (anthracycline-based) because of incomplete clinical response or 
physician preference (including 8 women with clinical complete response) and were 
included in the ITT analysis (Fig. 1). Dose modifications are described in Supplemental 
Table 1 (supplemental materials are available at http://jnm.snmjournals.org). Thirty-three 
patients received AC, and 2 received cisplatin, postoperatively.
Treatment Safety—Hematologic and nonhematologic toxicities are shown in 
Supplemental Table 2. There were no significant differences in adverse events between the 
arms. The preplanned masked interim toxicity analysis did not meet the criteria for early 
stopping.
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Treatment Efficacy—Overall, pCR was observed in 17 patients (27.4%; 95% confidence 
interval [CI], 16.9%–40.2%) in the ITT population, meeting the predefined aim of 25% in 
each arm: 8 in the vorinostat arm (25.8%; 95% CI, 11.9%–44.6%) and 9 in the placebo arm 
(29.0%; 95% CI, 14.2%–48.0%). Because the pCR rates in both arms were similar, we 
pooled the arms to obtain this overall pCR rate with a 95% CI. Of patients obtaining pCR, 
12 were ER- and PR-negative, 5 were ER- or PR-positive (2 with known BRCA mutations, 
1 in each arm, one of whom received preoperative nonstudy chemotherapy), and all were 
grade 3. When stratified by hormone receptor status, the pCR rate in the placebo arm was 
10.5% (2/19; 95% CI, 1.3%–33.1%) and in the vorinostat arm 15.8% (3/19; 95% CI, 3.4%–
39.6%) for patients with ER- or PR-positive disease. For patients with triple-negative breast 
cancer, the pCR rate was 58.3% (7/12; 95% CI, 27.6%–84.8%) in the placebo arm and 
41.7% (5/12; 95% CI, 15.2%–72.3%) in the vorinostat arm (Fig. 2). Additionally, we 
performed an analysis considering patients who received additional nonstudy preoperative 
chemotherapy as pathologic nonresponders, to provide a conservative estimate for the pCR 
rate with study therapy alone. The overall pCR rate was 17.7% (11/62; 95% CI, 9.2%–
29.5%), 16.1% for the vorinostat arm (5/31; 95% CI, 5.5%–33.7%), and 19.4% for placebo 
arm (6/31; 95% CI, 7.5%–37.5%).
Baseline and Change in Biomarkers and Correlation with Response to 
Therapy—All 62 patients underwent baseline study biopsy and 18F-FDG PET, and 59 
(95.2%) and 61 (98.4%) underwent both baseline and C1D15 biopsy and 18F-FDG PET, 
respectively. Baseline 18F-FDG PET occurred within 30 d before the initiation of study 
therapy (75% within 1 wk of initiation of therapy, range 0–30), and C1D15 18F-FDG PET 
occurred on day 15 in 66% of cases (range, days 14–22). 18F-FDG PET was performed 
before study biopsy in all but 4 cases (baseline) and in all cases at C1D15. No significant 
differences in the biomarkers were found between treatment groups, and thus a pooled 
analysis was performed using data from patients with valid 18F-FDG PET data at baseline 
and C1D15. Change in SULmax was evaluated in 59 women (16 pCR, 43 no pCR), where 3 
were not evaluable (technically invalid 18F-FDG PET data [n = 2] or no available 
C1D15 18F-FDG PET [n = 1]). Median baseline SULmax in pathologic responders was 
significantly higher than in pathologic nonresponders (7.6 vs. 5.3; P = 0.018; Table 2). A 
significant difference in change in SULmax was observed between pathologic responders 
and nonresponders (median percentage reduction, 63% vs. 33%; P = 0.003; Fig. 3; Table 2). 
Seventy-five percent of pathologic responders exhibited a 50% or greater reduction in 
SULmax at C1D15 versus 30% of nonresponders (P = 0.003; Table 2). Patients with a 50% 
or greater reduction in SULmax were more likely to achieve a pCR, as suggested by both 
univariate (odds ratio, 6.6; 95% CI, 1.9–27.3; P = 0.004) and multivariable analyses 
adjusting for hormone receptor status (odds ratio, 5.1; 95% CI, 1.3–22.7; P = 0.023; Table 
3). By receiver-operating-characteristic analysis, discrimination between patients with pCR 
(pathologic responders) and no pCR (pathologic nonresponders) resulted in an area under 
the curve of 0.76 (95% CI, 0.60–0.91), with a sensitivity of 0.75 and specificity of 0.74 at a 
cutoff of 52% reduction in SULmax that maximized the sum of sensitivity and specificity. 
Negative predictive value and positive predictive value were 89% and 52%, respectively. A 
post hoc sensitivity analysis was performed excluding patients who received additional 
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nonstudy preoperative therapy and demonstrated similar results (Supplemental Tables 3 and 
4).
Forty-four matched specimens (baseline, C1D15) were evaluable for change in Ki-67 (8 
pCR, 36 non-pCR); nonevaluable samples had no tumor cells present or Ki-67 unavailable 
at either or both time points. We did not observe statistically significant differences in 
baseline and C1D15 percentage change in Ki-67 between pathologic responders and 
nonresponders nor a significant change in ER status between before and after therapy 
(Supplemental Table 5).
DISCUSSION
We demonstrated that preoperative CP plus vorinostat or placebo was associated with 
similar pCR rates in women with HER2-negative breast cancer. The pCR rate observed 
overall in the ITT population (27%) was greater than initially predicted on the basis of 
historic data in unselected breast cancer subtypes (12). However, a proportion of patients 
received additional nonstudy preoperative chemotherapy per physician discretion, which 
likely had an impact on the assessment of the primary endpoint. pCR was observed only in 
women with grade 3 tumors and predominantly in those with triple-negative disease. 
Interestingly, of those with ER- or PR-positive tumors who experienced a pCR, 2 patients 
had BRCA mutations, suggesting that CP may warrant further evaluation in this population. 
These results are reflective of the high pCR rate observed, irrespective of hormone receptor 
status, in a recent study of neoadjuvant cisplatin in patients with BRCA1 mutations (13).
Early change in SUV on 18F-FDG PET has been investigated as a predictor of response to 
PST (8). In a prospective trial in which 104 patients with large (≥3 cm) or locally advanced 
breast cancer were randomized to 2 anthracycline/taxane-based neoadjuvant chemotherapy 
regimens, 18F-FDG PET scans were obtained at baseline and after 1 and 2 cycles of 
chemotherapy (14). A threshold of 45% decrease in SUV after the first cycle of 
chemotherapy correctly identified 11 of 15 patients who obtained a pCR, and those who did 
not obtain a pCR were identified with a negative predictive value of 90%. After the second 
cycle of chemotherapy, a threshold of 55% relative decrease in SUV predicted pCR. We 
enrolled a similar patient population, and all participants received a relatively homogeneous 
chemotherapy regimen. A meta-analysis of 19 studies and 920 patients with pCR aimed to 
predict pathologic response in primary breast lesions by 18F-FDG PET (15). The best 
correlation with pCR used a 55%–65% reduction rate cutoff value of SUV. An exploratory 
receiver-operating-characteristic analysis from our study indicated that a 52% reduction in 
SULmax predicted pCR, with a sensitivity of 75%, specificity of 74%, negative predictive 
value of 89%, and positive predictive value of 52% (area under the curve, 0.76; 95% CI, 
0.60–0.91). Other studies performed to date have been predominantly retrospective and 
associated with significant heterogeneity of the breast cancer subtypes investigated, 
chemotherapy administered, timing of imaging in relation to chemotherapy, and definitions 
of response to therapy (14,16–19). The significant difference we observed in median 
percentage reduction in SULmax on 18F-FDG PET between pathologic responders and 
nonresponders in a pooled analysis with a relatively large odds ratio suggests that SULmax 
is a promising biomarker for early prediction of treatment response to this regimen. Coupled 
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with others, our results provide valuable data regarding the optimal cut point of reduction in 
SULmax, which can be used in future studies designed to assess whether altering therapy 
based on early changes will be associated with improved pCR. This study was designed 
before the PET Response Criteria in Solid Tumors 1.0 were published, but it is expected that 
SULpeak (the highest-valued 1-cm3 spheric volume of interest for which the center point 
lies within the volume boundary) changes would provide similar results, possibly with 
greater precision than SULmax (11).
Strengths of our study include the multicenter prospective randomized and placebo-
controlled design. All 62 patients underwent baseline 18F-FDG PET and biopsy, with almost 
all patients undergoing serial 18F-FDG PET scans and biopsies, an invaluable resource for 
correlative analyses. Study sites were provided with 18F-FDG PET imaging protocol 
recommendations to achieve a high level of multisite consistency. This consistency was 
documented by a few cases with uptake periods outside the specified range of 50–70 min 
after injection (n = 10/62), only 3 patients with blood sugar readings at the time of imaging 
in excess of 150 mg/dL, though all were below 200 mg/dL, and different scanners being 
used between baseline and follow-up scans in only 3 of the 62 cases. Because of the small 
numbers involved, it is unlikely that the use of different scanners between baseline and 
follow-up affected the study results. Central analysis of 18F-FDG PET was successful, and 
90% of images were evaluable for change in SULmax. Finally, we chose an early time point 
for the second 18F-FDG PET scan (after 2 wk) to define as early as possible in the treatment 
paradigm those patients who will benefit from an alternative approach. A rapid and 
significant decrease in glucose metabolism as early as 8 d after the administration of 1 cycle 
of combination chemotherapy in women who responded to the regimen has been previously 
observed and can allow for a rapid change in therapy for women who are not expected to 
derive benefit (8). This has theoretic advantages over later time points in terms of 
discrimination abilities between pCR and non-pCR (11,20).
Limitations of our study include that a proportion of women received additional 
anthracycline-based preoperative chemotherapy after study treatment, which may 
complicate both the evaluation of our primary endpoint and the role of 18F-FDG PET in 
predicting treatment response. However, post hoc sensitivity analysis, which excluded 
patients who received preoperative nonstudy chemotherapy, yielded similar results 
(Supplemental Tables 3 and 4). Only 72% of matched samples were evaluable for Ki-67 
analysis, partly because of the lack of viable tumor cells in C1D15 specimens, which may 
have been due to early treatment effect. The challenges surrounding serial Ki-67 
measurement in tumor samples have been previously described (21). These results suggest 
that the ability to quantify and image the entire tumor by 18F-FDG PET imaging may be an 
advantage over a biopsy of a small region of tumor. In a small number of cases (n = 4), 
baseline study biopsy was performed before 18F-FDG PET, which may have inflated the 
SULmax value due to an inflammatory response. The cost associated with serial 18F-FDG 
PET imaging, as well as additional radiation exposure over and above standard of care, may 
also be a barrier to implementing change in SULmax as a treatment-selection biomarker in 
the clinic. However, a noninvasive biomarker that is readily available may be preferable to a 
tissue-based biomarker, which requires additional procedures for patients. Our study did not 
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incorporate serial MR imaging, which may be an alternative to 18F-FDG PET and associated 
with less radiation exposure (20). Newer 18F-FDG PET cameras and CT algorithms can also 
acquire high-quality images with lower radiation doses.
CONCLUSION
Our study confirms the feasibility of conducting multicenter neoadjuvant studies that add 
novel agents to chemotherapy backbones and incorporate serial tissue biopsies and 
quantitative imaging for biomarker development. Although our study did not indicate a 
benefit for the addition of vorinostat to CP, the pCR rate observed suggests a potential role 
for platinum agents in specific breast cancer subtypes, namely high-grade triple-negative or 
BRCA-associated tumors. Future studies will use the optimal cut point of reduction in 
SULmax we have identified to determine whether altering therapy based on early changes in 
SULmax is of clinical utility.
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CONSORT flow diagram for phase II. All 73 patients who signed consent for formal 
eligibility assessment are included.
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pCR rates overall and by subgroup (ITT analysis).
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Box plots of reduction in SULmax in patients with pCR and non-pCR. Horizontal line inside 
box shows median. Lower and upper hinges of box represent 25th and 75th percentiles, 
respectively. ● = actual values of percentage reduction in SULmax.
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TABLE 1
Patient Characteristics
Characteristic Vorinostat arm (n = 31) Placebo arm (n = 31) Overall (n = 62)
Age (y)
 Median 48 48 48
 Range 31–68 24–72 24–72
Race
 Caucasian 24 (77) 19 (61) 43 (69)
 Black 5 (16) 8 (26) 13 (21)
 Other 2 (7) 4 (13) 6 (10)
Eastern Co-operative Oncology Group Performance Status
 0 29 (94) 30 (97) 59 (95)
 1 2 (6) 1 (3) 3 (5)
Tumor size (cm)
 Median 4 5 4
 Range 1.5–11.5 1.7–18 1.5–18
Baseline nodal status
 Negative 14 (45) 10 (32) 24 (39)
 Positive 17 (55) 21 (68) 38 (61)
Tumor grade
 2 7 (23) 11 (35) 18 (29)
 3 24 (77) 20 (65) 44 (71)
Receptor status
 ER-negative/PR-negative 12 (39) 12 (39) 24 (39)
 ER-positive/PR-positive 10 (32) 12 (39) 22 (36)
 ER-positive/PR-negative 6 (19) 6 (19) 12 (19)
 ER-negative/PR-positive 3 (10) 1 (3) 4 (6)
BRCA status
 BRCA1/2 mutation 4 (13) 3 (10) 7 (11)
 BRCA-negative 7 (22) 9 (29) 16 (26)
 Unknown 20 (65) 19 (61) 39 (63)
Data in parentheses are percentages.
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TABLE 2
Baseline and Change in SULmax Between Pathologic Responders and Nonresponders
Variable Responders (n = 16) Nonresponders (n = 43) P*
Baseline SULmax
 Mean ± SD 8.2 ± 3.3 5.9 ± 3.5
 Median 7.6 (range, 4.3–15.1) 5.3 (range, 1.4–21.0) 0.015
Percentage change in SULmax
 Mean ± SD 55.5 ± 23.6 30 ± 32.5
 Median 63.0 (range, 4.4–85.3) 32.9 (range, −84.2 to 77.1) 0.003
 ≥50% reduction (n) 12 (75.0%) 13 (30.2%) 0.003
*
Exact Wilcoxon rank sum test for continuous variables and Fisher exact test for binary variables.
Pooled ITT analysis.
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TABLE 3
Analysis of Association of SULmax with Pathologic Response
Variable
Univariate analysis Multivariable analysis*
Odds ratio P Adjusted odds ratio Adjusted P
Baseline SULmax 1.18 (1.01–1.42) 0.051 1.07 (0.88–1.30) 0.469
Percentage change in SULmax 1.04 (1.01–1.08) 0.011 1.03 (1–1.07) 0.057
Percentage change in SULmax, ≥50% vs. <50% 6.6 (1.9–27.3) 0.004 5.1 (1.3–22.7) 0.023
*
Multivariable logistic regression adjusting for ER and PR status.
Pooled ITT analysis. Data in parentheses are 95% CIs.
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